AB0360 Impact of Abatacept on Disease Activity and Functional Status in Patients with Different Duration of Rheumatoid Arthritis
| Autor: | Y. Sigidin, E. Aronova, Galina Lukina, D.E. Karateev, E. Luchihina, Nasonov El, Svetlana Glukhova, M. Kanonirova |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty business.industry Abatacept Immunology Significant difference Dosing regimen medicine.disease General Biochemistry Genetics and Molecular Biology Surgery Disease activity Rheumatology Rheumatoid arthritis Internal medicine Immunology and Allergy Medicine Functional status In patient skin and connective tissue diseases business Adverse effect medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 75:1026.2-1026 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Background Abatacept (ABA) is a selective co-stimulation modulator, which is widely used in treatment of RA. There isn9t enough data about its effectiveness and impact on functional status in patients with early (ERA) and long-standing (LS) rheumatoid arthritis (RA). Objectives To assess the impact of ABA on disease activity and functional status in patients with different duration of RA. Methods 85 patients (pts) with active RA and an inadequate response to synthetic DMARDs or biologics were enrolled in the study. They were grouped into 2 arms based on RA duration: less than three years (early RA) and more than three years (LS RA), i.e. 51% and 49% pts in each group, respectively. Most of them were middle aged females (48,8±13,5 years) with high disease activity (DAS28=5,25±1,15), RF-positive (76,7%) and ACPA-positive (73,1%). ABA (10 mg/kg) was administered intravenously following the adult intravenous dosing regimen. Disease activity was assessed by DAS28, functional status by HAQ-DI and results by EULAR criteria every 12 weeks. Results Before treatment DAS28 in ERA pts was 5,1±0,9, in LS RA – 5,3±1,3 and HAQ-DI in ERA pts was 1,3±0,6, in LS RA - 1,6±0,9. In three months after ABA therapy initiation a significant improvement in DAS28 and HAQ-DI was achieved in both groups ( p Conclusions ABA has shown significant improvement in reduction of disease activity and improvement in functional status in pts with RA. No significant difference was seen between the groups of ERA and LS RA by EULAR criteria. However, pts in ERA group had significant improvement of HAQ-DI comparing with LS RA group. ABA has good safety profile, adverse events were registered only in 20% of patients. Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|